Neurocrine Biosciences, Inc. NBIX

NBIX Company Overview

Neurocrine Biosciences, Inc. is a U.S.-based biopharmaceutical company focused on discovering, developing, and commercializing treatments for neurological, neuroendocrine, and neuropsychiatric disorders. The company operates within the biotechnology and specialty pharmaceutical industries, with a primary emphasis on central nervous system (CNS) diseases and endocrine-related conditions. Its principal revenue driver is INGREZZA (valbenazine), a vesicular monoamine transporter 2 (VMAT2) inhibitor approved for tardive dyskinesia and chorea associated with Huntington’s disease. The company also generates collaboration and licensing revenue through partnerships with larger pharmaceutical companies.

Neurocrine Biosciences serves neurologists, psychiatrists, movement disorder specialists, endocrinologists, and specialty healthcare providers primarily in the United States, while maintaining development and partnership activities internationally. The company has positioned itself as a focused neuroscience innovator with expertise in movement disorders, neuropsychiatry, and rare endocrine diseases. Founded in 1992 and headquartered in San Diego, California, Neurocrine evolved from an early-stage neuroscience research company into a commercially successful biotechnology firm following the launch and expansion of INGREZZA and subsequent pipeline development activities.